Vimarsana
Biggest News Aggregation in the World

Page 7 - Presentation Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentation Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentation Details Today - Breaking & Trending Today

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 - Vimarsana News

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience Pooled Analysis Shows 77.8% Objective Response Rate in...

Cerevance Announces Presentation at the 34th International Symposium on ALS/MND - Vimarsana News

Cerevance Announces Presentation at the 34th International Symposium on ALS/MND

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced a poster presentation at the 34th International Symposium on ALS/MND, taking place in Basel, Switzerland from December 6 – 8, 2023. Presentation details Title: The two-pore potassium channel KCNK13 as a target to modulate neuroinflammation in Amyotrophic Lateral SclerosisOverview: Cerevance's unique NETSseq platform has the r

Source: yahoo.com
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference - Vimarsana News

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E....

monday.com Announces Third Quarter 2023 Results - Vimarsana News

monday.com Announces Third Quarter 2023 Results

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--Nov 13, 2023--

CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023 - Vimarsana News

CDR-Life Presents Findings from Two Studies in Preparation of Phase 1 Trial with Immunotherapy CDR404 for Treatment of Solid Tumors at SITC 2023

Therapeutic potential of CDR404, as a first-of-its-kind precision immunotherapy for HLA-A*02:01+ patients with MAGE-A4+ squamous non-small cell lung carcinoma (SQ-NSCLC) Development of a Quantitative Systems Pharmacology (QSP) model to facilitate discovery of safe and efficacious doses for upcoming Phase 1 trial ZÜRICH, Switzerland, Nov. 03, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc., in the run-up to initiation of its first Phase 1 clinical trial, presented two posters for CDR404, a first-of-its-ki

Source: yahoo.com